605116.SH
奥锐特
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 19.48
−2.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.7B | 1.5B | 1.3B | 1.0B |
| Cost of Revenue | 708.2M | 684.6M | 611.5M | 556.6M | 487.7M |
| Gross Profit | 976.5M | 1.0B | 864.2M | 706.0M | 520.4M |
| Operating Expenses | |||||
| R&D Expense | 159.0M | 153.4M | 146.3M | 136.9M | 117.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 166.6M | 165.9M | 170.2M | 169.7M | 135.4M |
| Selling & Marketing Expense | 140.2M | 131.4M | 130.5M | 100.8M | 39.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 530.6M | 498.5M | 440.6M | 400.7M | 272.6M |
| Cost and Expenses | 1.2B | 1.2B | 1.1B | 957.3M | 760.2M |
| Operating Income (EBIT) | 456.2M | 520.6M | 410.5M | 330.7M | 241.3M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 453.9M | 518.3M | 407.4M | 329.1M | 240.8M |
| Income Tax Expense | 60.2M | 69.1M | 52.6M | 40.0M | 32.5M |
| Bottom Line | |||||
| Net Income | 393.7M | 449.2M | 354.8M | 289.4M | 211.0M |
| Earnings from Cont. Ops | 393.7M | 449.2M | 354.8M | 289.1M | 208.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 393.7M | 449.2M | 354.8M | 289.4M | 211.0M |
| Per Share | |||||
| Basic EPS | CN¥0.98 | CN¥1.12 | CN¥0.89 | CN¥0.71 | CN¥0.52 |
| Diluted EPS | CN¥0.98 | CN¥1.10 | CN¥0.89 | CN¥0.71 | CN¥0.52 |
| Revenue Per Share | CN¥4.22 | CN¥4.23 | CN¥3.70 | CN¥3.10 | CN¥2.48 |
| Shares | |||||
| Basic Shares Outstanding | 399.5M | 401.1M | 398.6M | 407.6M | 405.7M |
| Diluted Shares Outstanding | 399.5M | 401.1M | 398.6M | 407.6M | 405.7M |
| Profitability Metrics | |||||
| EBITDA | — | 642.2M | 495.1M | 407.4M | 307.8M |
| D&A | — | 121.6M | 84.6M | 76.7M | 66.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026